Discontinued — last reported Q1 '26
Products & Services · Sales
Ohtuvayre — Sales
This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market demand and successful commercial execution, whereas a decrease may signal market saturation, competitive pressure, or loss of exclusivity.
Detailed definition
This metric measures the total gross revenue generated from the sale of the Ohtuvayre product line after accounting for...
Peer comparison
Comparable to product-specific revenue reporting found in the segment disclosures of major global pharmaceutical and biotechnology firms.
Metric ID:
mrk_segment_ohtuvayre_salesHistorical Data
10 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $131.00M |
Range$0.00 – $131.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s ohtuvayre — sales?
- Merck & Co. (MRK) reported ohtuvayre — sales of $131.00M in Q1 2026.
- What does ohtuvayre — sales mean?
- The total revenue earned from selling the Ohtuvayre product.